Abstract: The present invention provides dry powder formulations comprising nicotine, methods of using the same, and methods for making the same. The dry powder formulations may further comprise excipients, therapeutic agents, and flavor components. The dry powder formulations may be manufactured by dry processes and wet processes.

Abstract: A method of treating a patient having a lung condition that includes identifying a target haemoglobin-carbon monoxide level in the blood of the patient. The method also includes administering, to the patient, carbon monoxide at a first concentration for an initial time period, and measuring the haemoglobin-carbon monoxide level in the blood of the patient. The method also includes calculating, based on the measured haemoglobin-carbon monoxide level and the target haemoglobin-carbon monoxide level, a dose of carbon monoxide required to attain the target haemoglobin-carbon monoxide level within a determined time period. The method also includes administering, to the patient, the calculated dose of carbon monoxide for the determined time period to attain the target haemoglobin-carbon monoxide level in the blood of the patient.

Abstract: The present invention provides dry powder formulations comprising nicotine, methods of using the same, and methods for making the same. The dry powder formulations may further comprise excipients, therapeutic agents, and flavor components. The dry powder formulations may be manufactured by dry processes and wet processes.

Abstract: A device for adding a flavor and/or cough suppressant component to an inhaler is described. The device includes a housing having an interior chamber, wherein the housing includes at least one air inlet and at least one air outlet connected to the interior chamber, thereby forming an airflow pathway through the interior chamber, and at least one flavoring and/or cough suppressant component positioned within the interior chamber, wherein the housing is attachable to an exterior surface of an inhaler having at least one air inlet, such that the at least one air outlet of the device aligns with the at least one air inlet of the inhaler to form an airflow path through the device and into the inhaler.

Abstract: A device for accessing dry powder within a sealed chamber is described. The device includes a hollow housing having a proximal end opening, a primary distal end opening and a secondary distal end opening, at least one wing structure extending from the outer surface of the housing that is positioned distally from the primary distal opening. Also described is a dry powder inhaler having a housing, a penetrating component for accessing dry powder within a sealed chamber, and a mouthpiece, where the mouthpiece is connected to the proximal end opening of the penetrating component, and wherein the at least a portion of the distal end of the penetrating component is positioned within the inhaler housing.

Abstract: This invention relates to nicotine microparticles formulations made with the help of a diketopiperazine compound, in particular fumaryl diketopiperazine (FDKP). The invention relates to the various types of microparticles that can be made, in particular nicotine-coated and nicotine-loaded microparticles. The invention further relates to the various methods that can be used in making the microparticles. One particular method involves making FDKP microparticles which are further surface-coated with nicotine. Another particular method involves mixing nicotine with FDKP2? and/or FDKP and then forming microparticles which contain nicotine throughout their volume. The invention also relates to the use of this microparticles in tobacco related therapies, such as tobacco replacement or tobacco withdrawal.

Abstract: The present invention relates to a liquid nitric oxide releasing solution (NORS) comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of nitric oxide gas (gNO). The present invention also relates to a liquid NORS comprised of at least one nitrite compound having a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment of a wound in a human, the method comprising administering to the human a liquid NORS comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of gNO.

Abstract: A device and method for reducing heat loss in at least one region of a subject's body is described. The device includes a mask component, a heat releasing reservoir, and a conduit connecting the mask component to the heat releasing reservoir and creating an airflow path therethrough, wherein the heat releasing reservoir includes at least one air permeable region that is impermeable to condensed water. Heat loss is reduced by the subject positioning the mask over the mouth and/or nose, positioning the heat releasing reservoir over the region of the subject's body, and passing warmed air exhaled by the subject into the mask through the conduit and into the heat releasing reservoir, such that the warmed air passes through the heat releasing reservoir while retaining condensed water within the heat releasing reservoir, thereby increasing the temperature of the air surrounding the at least one region of the subject's body.

Abstract: A dry powder inhaler dispenses a partial dosage of a powder from a dry powder chamber during a single user inhalation. In certain embodiments, the dry powder chamber is a dry powder capsule that spins in a chamber with a protrusion for limiting the spin of the capsule. In certain embodiments, a capsule slides in a proximal and distal direction for dispensing partial dosages of powder medicament. Air inlets in communication whit the external environment can be included in the inhaler housing for generating a smooth inhalation experience for the user and facilitating operation of partial dosage mechanisms. In other embodiments, a hinged member, sliding member, rotating member, spring tensioned member, pressure actuated valve, dry powder chamber with patterned holes or combinations of these are used as a mechanism for dispensing a partial dosage of powder medicament during a single inhalation.

Abstract: Described is a dry powder inhaler for inhalation of a dry powder composition. The inhaler includes an external housing that defines an internal passage. The inhaler also includes a mouthpiece, a compartment for holding a dry powder capsule or powder reservoir, and a powder fluidization and deagglomeration apparatus for directing airflow to the dry powder to generate airborne powder particles within the internal passage. When a user inhales through the mouthpiece, a first airflow pattern is generated that has a first airflow resistance, during which the fluidization and deagglomeration apparatus generates airborne dry powder particles within the internal passage. Upon reaching a threshold negative pressure value within the internal passage of the inhaler, a second airflow pattern is generated having a second airflow resistance that is lower than the first airflow resistance, which pulls the airborne dry powder into the user's lungs during the inhalation. Embodiments of elastomeric valves are also described.

Abstract: The present invention provides in part dry powder inhaler (DPI) devices for dispensing dry powder and methods for using the same. The DPI devices feature exchangeable cartridges having drum mechanisms that prepare metered doses of dry powder, and are able to direct air in a turbulent manner sufficient to entrain and deagglomerate a dose of dry powder for delivery into a user's lungs. The DPI devices feature a reservoir of dry powder advanced by a plunger, as well as a gauge that advances with the plunger to indicate the amount of dry powder remaining in the reservoir.

Abstract: The present invention provides for systems and methods for inhaled CO therapy to prevent, attenuate, or delay processes that accelerate the loss of organ or tissue function, thereby increasing the lifespan of transplanted organs or tissues, or slowing the decline of native organs or tissues, or delaying the need for replacement of diseased native organs with organ transplants. Such biological processes that are prevented, attenuated, or delayed include chronic persistent inflammation, fibrosis, scarring, as well as immunologic or autoimmune attack.

Abstract: The present invention relates to devices, systems, and methods for a safety interlock for a gas cylinder. The interlock device of the present invention can prevent a gas cylinder from being removed from a gas administration device as long as gas remains in the gas cylinder.

Abstract: The present invention provides for systems and methods for inhaled CO therapy to prevent, attenuate, or delay processes that accelerate the loss of organ or tissue function, thereby increasing the lifespan of transplanted organs or tissues, or slowing the decline of native organs or tissues, or delaying the need for replacement of diseased native organs with organ transplants. Such biological processes that are prevented, attenuated, or delayed include chronic persistent inflammation, fibrosis, scarring, as well as immunologic or autoimmune attack.

Abstract: The present invention provides a spacer device having a flow rate spirometer. The flow rate indicator allows users to use a measured, consistent flow rate leading to improved synchronicity and actuation.

Abstract: The present invention relates to a liquid nitric oxide releasing solution (NORS) comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of nitric oxide gas (gNO). The present invention also relates to a liquid NORS comprised of at least one nitrite compound having a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment of a wound in a human, the method comprising administering to the human a liquid NORS comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of gNO.

Abstract: A gas flow regulating device including a housing assembly, an inlet tube assembly, and a biasing device. The housing assembly has a main housing, a valve seat body, and a distal plate forming an outlet orifice. The inlet tube assembly includes a proximal inlet end, a tube forming a lumen, and a flange, and is slidably disposed within the main housing, biased to an open state by the biasing device. The flange separates middle and constant pressure chambers within the housing assembly. The inlet tube assembly is transitionable to a closed state in response to pressure in the constant pressure chamber to generate a relatively constant flow rate of air exiting the device via the outlet orifice.

Abstract: The present invention provides dry powder formulations comprising nicotine, methods of using the same, and methods for making the same. The dry powder formulations may further comprise excipients, therapeutic agents, and flavor components. The dry powder formulations may be manufactured by dry processes and wet processes.

Abstract: A dry powder inhalation device includes in certain embodiments a spin chamber and a cartridge for holding multiple capsules. The capsules contain a dry powder that in certain embodiments includes methacholine. In certain embodiments, an adjustable limiting mechanism is configured to limit inhaled volume through the second passageway. In certain embodiments, the cartridge moves linearly or radially though a portion of the device. In certain embodiments, capsules in the cartridge align with a port in the spin chamber to load into the spin chamber. User inhalation on a mouthpiece of the device generates a vortical airflow and causes the capsules to spin within the chamber, releasing a portion of the dry powder for inhalation. In certain embodiments, the device is used for an inhalation diagnostic challenge.

Abstract: The present invention provides dry powder formulations comprising nicotine, methods of using the same, and methods for making the same. The dry powder formulations may further comprise excipients, therapeutic agents, and flavor components. The dry powder formulations may be manufactured by dry processes and wet processes.